Open access · CC-BY
via OpenAlex
Mesenchymal Stem Cells: Healthy At Any Age
Troy C. Lund, Amanda Kobs, Bruce R. Blazar, Jakub Tolar
Transplantation and Cellular Therapy · 2010
Abstract
Mesenchymal Stem Cells (MSC) are gaining in popularity as an experimental therapy for a number of conditions including graft-versus-host disease, Crohn's disease, myocardial infarction, etc. Most applications require that MSCs be expanded to achieve an adequate cell-dose for therapy. Prior data suggest that MSC undergo aging in culture and that MSC from older donors undergo earlier senescence(definition) than MSC from younger donors. We have observed over 100 MSC expansion cultures and it seemed that early in the expansion period MSC from any age donor microscopically appeared healthy and showed no difference upon differentiation into adipogenic, osteogenic, or cartilage lineages. We hypothesized that MSC from any age donor would have similar cellular fitness when expanded under incubation conditions and limited passage to mimic cell handling that would be used in a clinical preparation. We have compared the expression of several markers of aging in MSCs obtained from a subset of 120 donors over a wide range of ages (8 months to 60 years). We find that although MSC from older individuals produced slightly fewer cells over a fixed number of passages and have a slightly longer doubling time (54 hrs vs 42 hrs), a satisfactory clinical product can still be obtained (multiple doses at >106 cell/kg). When MSC from young (0.8-6 years) and old (43-60 years) were compared there was no difference in cell surface markers, lipofuscin, migration ability, or expression of aging markers such as iNOS, PGE2, p16, and SOD. SOD activity (0.025 vs 0.028 U/ml) and oxidative challenge death rate to hydrogen peroxide were not significantly different (1% vs 1.5%, p=0.14). Morphology by light microscopy and extent of qualitative differentiation into osteogenic, adipogenic, and cartilage cell types were also similar in old and young donor derived MSC. Finally, telomeres did not show a significant difference in length between young and old donor-derived MSC early in passage. We conclude that age may not need to be considered when determining a potential MSC donor especially in light of the fact that many clinical applications require only a limited culture time (19-21 days) to achieve a sufficient number of cells for a useful clinical product.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.bbmt.2009.12.185
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Lund, T.C., Kobs, A., Blazar, B.R., & Tolar, J. (2010). Mesenchymal Stem Cells: Healthy At Any Age. <em>Transplantation and Cellular Therapy</em>. https://doi.org/10.1016/j.bbmt.2009.12.185
Vancouver
Lund TC, Kobs A, Blazar BR, Tolar J. Mesenchymal Stem Cells: Healthy At Any Age. Transplantation and Cellular Therapy. 2010. doi:10.1016/j.bbmt.2009.12.185.
BibTeX
@article{troy2010Mesenc,
title = {Mesenchymal Stem Cells: Healthy At Any Age},
author = {Troy C. Lund and Amanda Kobs and Bruce R. Blazar and Jakub Tolar},
journal = {Transplantation and Cellular Therapy},
year = {2010},
doi = {10.1016/j.bbmt.2009.12.185},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Stem Cell Research & Therapy 2018
Open access · CC-BY
Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro
BMC Cell Biology 2008
Open access · CC-BY
Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells
BMC Cell Biology 2006
Open access · CC-BY
Aging of mesenchymal stem cell in vitro
BMC Cell Biology 2011
Open access · CC-BY
Age-related changes in rat bone-marrow mesenchymal stem cell plasticity
Aging Cell 2022
Open access · CC-BY
NAP1L2 drives mesenchymal stem cell senescence and suppresses osteogenic differentiation
Antioxidants and Redox Signaling 2017
Open access · OA